400-921-8278
| Catalog_no | ADMC0751 |
| Product_name | Afuresertib HCl (GSK-2110183) |
| Category | 抑制剂与激动剂 |
| Size | 10mg/50mg/100mg |
| Price | 1660.00/5000.00/7220.00 |
| Specificity | Target: PKA . Fields: Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM |
| Dilution | Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), 4 nM (PKG1β)[1] |
| Purification | >98% |
| Concentration | 靶点：PKA;IC50：Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), 4 nM (PKG1β)[1] |
| Storage_stability | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
| othername | Afuresertib，GSK 2110183，GSK2110183 |
| Observed_band | 463.78 |
| Notes | Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), |
| Instructions | 
查看与下载 |
| Share |
 |
Copyright © 2021 苏州博特龙免疫技术有限公司 版权所有 ，苏ICP备2021013855号-1
苏公网安备32050702011981号 
